EKF Diagnostics Acquires Selah Genomics and DiaSpect Medical
By LabMedica International staff writers Posted on 30 Apr 2014 |
EKF Diagnostics (Cardiff, Wales, UK), a global in vitro diagnostics business, has acquired Selah Genomics, Inc. and DiaSpect Medical AB, enhancing its hemoglobin analysis and personalized medicine capabilities. Sweden based DiaSpect manufactures desktop hemoglobin analyzers, while Selah, of South Carolina (USA), is a service provider that supplies molecular diagnostics tests for the development of personalized medicine.
The integration of DiaSpect’s product line into the existing portfolio of EKF hemaglobin analyzers will enable the provision of an analyzer to meet any need. The patented DiaSpect Hb-system provides instant results from one drop of whole blood. It is suitable for use in dry or humid conditions, and the broad-spectrum photometer together with the reagent-free cuvette is reliable and cost-effective. This desktop device will join the point of care (POC) Hemo Control (Hemo Point H2 in the USA) and the hand-held, portable STAT-Site hemoglobin analyzer.
The acquisition of Selah Genomics enables EKF to extend its molecular diagnostics offering to support healthcare providers and the pharmaceutical industry with advanced molecular and genomic diagnostic services. The easy-to-use service provides doctors with a sample kit, and once they have obtained a swab from the patient, it is simply sealed and posted back for analysis. Resulting data can be used to develop personalized treatment plans.
Combined with the recent acquisition of Separation Technology, Inc. this purchase has strengthened EKF’s product and services offering, positioning EKF at the forefront of the POC hematology testing provision. EKF now offers a comprehensive and cost-effective product range, as well as being able to participate in personalized medicine; an area which is quickly becoming important in the in vitro diagnostic (IVD) industry.
Julian Baines, CEO of EKF, commented, “These acquisitions provide us with a huge opportunity to establish ourselves as a leading global player in point of care hemoglobin testing and to consider our position in molecular diagnostics and personalized medicine, an area which we consider to be one of the most exciting in diagnostics.”
EKF Diagnostics Holdings plc which includes the EKF Diagnostics, EKF Molecular, Stanbio Laboratory, Separation Technology Inc, DiaSpect, and Selah Genomics brands specializes in the development, production, and worldwide distribution of point-of-care blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. Its new molecular division focuses on molecular and companion diagnostics.
Related Links:
EKF Diagnostics
The integration of DiaSpect’s product line into the existing portfolio of EKF hemaglobin analyzers will enable the provision of an analyzer to meet any need. The patented DiaSpect Hb-system provides instant results from one drop of whole blood. It is suitable for use in dry or humid conditions, and the broad-spectrum photometer together with the reagent-free cuvette is reliable and cost-effective. This desktop device will join the point of care (POC) Hemo Control (Hemo Point H2 in the USA) and the hand-held, portable STAT-Site hemoglobin analyzer.
The acquisition of Selah Genomics enables EKF to extend its molecular diagnostics offering to support healthcare providers and the pharmaceutical industry with advanced molecular and genomic diagnostic services. The easy-to-use service provides doctors with a sample kit, and once they have obtained a swab from the patient, it is simply sealed and posted back for analysis. Resulting data can be used to develop personalized treatment plans.
Combined with the recent acquisition of Separation Technology, Inc. this purchase has strengthened EKF’s product and services offering, positioning EKF at the forefront of the POC hematology testing provision. EKF now offers a comprehensive and cost-effective product range, as well as being able to participate in personalized medicine; an area which is quickly becoming important in the in vitro diagnostic (IVD) industry.
Julian Baines, CEO of EKF, commented, “These acquisitions provide us with a huge opportunity to establish ourselves as a leading global player in point of care hemoglobin testing and to consider our position in molecular diagnostics and personalized medicine, an area which we consider to be one of the most exciting in diagnostics.”
EKF Diagnostics Holdings plc which includes the EKF Diagnostics, EKF Molecular, Stanbio Laboratory, Separation Technology Inc, DiaSpect, and Selah Genomics brands specializes in the development, production, and worldwide distribution of point-of-care blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. Its new molecular division focuses on molecular and companion diagnostics.
Related Links:
EKF Diagnostics
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus